WO2002083736A3 - G-protein coupled receptor molecules and uses thereof - Google Patents

G-protein coupled receptor molecules and uses thereof Download PDF

Info

Publication number
WO2002083736A3
WO2002083736A3 PCT/US2002/004397 US0204397W WO02083736A3 WO 2002083736 A3 WO2002083736 A3 WO 2002083736A3 US 0204397 W US0204397 W US 0204397W WO 02083736 A3 WO02083736 A3 WO 02083736A3
Authority
WO
WIPO (PCT)
Prior art keywords
coupled receptor
protein coupled
polypeptides
gpcr
receptor molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/004397
Other languages
French (fr)
Other versions
WO2002083736A2 (en
Inventor
Steven G Elliott
Norma Rogers
Leigh Anne Busse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to CA002438107A priority Critical patent/CA2438107A1/en
Priority to AU2002303091A priority patent/AU2002303091B2/en
Priority to JP2002581491A priority patent/JP2005503124A/en
Priority to MXPA03007270A priority patent/MXPA03007270A/en
Priority to EP02731091A priority patent/EP1379656A2/en
Publication of WO2002083736A2 publication Critical patent/WO2002083736A2/en
Anticipated expiration legal-status Critical
Publication of WO2002083736A3 publication Critical patent/WO2002083736A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)

Abstract

The present invention provides G-Protein Coupled Receptor (GPCR) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing GPCR polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with GPCR polypeptides.
PCT/US2002/004397 2001-02-14 2002-02-14 G-protein coupled receptor molecules and uses thereof Ceased WO2002083736A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002438107A CA2438107A1 (en) 2001-02-14 2002-02-14 G-protein coupled receptor molecules and uses thereof
AU2002303091A AU2002303091B2 (en) 2001-02-14 2002-02-14 G-protein coupled receptor molecules and uses thereof
JP2002581491A JP2005503124A (en) 2001-02-14 2002-02-14 G protein-coupled receptor molecule and use thereof
MXPA03007270A MXPA03007270A (en) 2001-02-14 2002-02-14 G-protein coupled receptor molecules and uses thereof.
EP02731091A EP1379656A2 (en) 2001-02-14 2002-02-14 G-protein coupled receptor molecules and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26904001P 2001-02-14 2001-02-14
US60/269,040 2001-02-14

Publications (2)

Publication Number Publication Date
WO2002083736A2 WO2002083736A2 (en) 2002-10-24
WO2002083736A3 true WO2002083736A3 (en) 2003-11-20

Family

ID=23025554

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/004397 Ceased WO2002083736A2 (en) 2001-02-14 2002-02-14 G-protein coupled receptor molecules and uses thereof

Country Status (7)

Country Link
US (1) US20030171541A1 (en)
EP (1) EP1379656A2 (en)
JP (1) JP2005503124A (en)
AU (1) AU2002303091B2 (en)
CA (1) CA2438107A1 (en)
MX (1) MXPA03007270A (en)
WO (1) WO2002083736A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6902902B2 (en) 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
WO2008063321A2 (en) * 2006-10-13 2008-05-29 Janssen Pharmaceutica N.V. Gpr81-ligand complexes and their preparation and use
GB2456236B8 (en) 2007-03-22 2009-12-09 Heptares Therapeutics Ltd Stable muscarinic receptor mutants
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
WO2013021206A2 (en) 2011-08-10 2013-02-14 Heptares Therapeutics Limited Stable proteins
ES2676827T3 (en) 2012-06-01 2018-07-25 Heptares Therapeutics Limited essays
WO2014160772A1 (en) * 2013-03-27 2014-10-02 Uab Research Foundation Stepwise differentiation of stem cells for the production of eukaryotic membrane proteins
WO2020251697A2 (en) * 2019-04-30 2020-12-17 The Trustees Of Columbia University In The City Of New York Scalable peptide-gpcr intercellular signaling systems
CN110252079B (en) * 2019-05-08 2022-03-15 天津大学 Remote transmission method for smell

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955308A (en) * 1997-06-18 1999-09-21 Smithkline Beecham Corporation cDNA clone HEAOD54 that encodes a human 7-transmembrane receptor
WO2001036471A2 (en) * 1999-11-17 2001-05-25 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human g protein-coupled receptors
WO2001073029A2 (en) * 2000-03-27 2001-10-04 Pe Corporation (Ny) Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
WO2001074904A2 (en) * 2000-03-31 2001-10-11 Curagen Corporation G-protein coupled receptors and nucleic acids encoding same
WO2001087937A2 (en) * 2000-05-18 2001-11-22 Incyte Genomics, Inc. G-protein coupled receptors
WO2001098330A2 (en) * 2000-06-20 2001-12-27 Euroscreen S.A. A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS
WO2002002767A1 (en) * 2000-07-04 2002-01-10 Takeda Chemical Industries, Ltd. Novel g protein-coupled receptor protein and dna thereof
GB2365868A (en) * 2000-05-30 2002-02-27 Smithkline Beecham Corp Polynucleotides and polypeptides of the G-protein coupled receptor AXOR87

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2388865A1 (en) * 1999-11-16 2001-05-25 Pharmacia & Upjohn Company Novel g protein-coupled receptors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955308A (en) * 1997-06-18 1999-09-21 Smithkline Beecham Corporation cDNA clone HEAOD54 that encodes a human 7-transmembrane receptor
WO2001036471A2 (en) * 1999-11-17 2001-05-25 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human g protein-coupled receptors
WO2001073029A2 (en) * 2000-03-27 2001-10-04 Pe Corporation (Ny) Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
WO2001074904A2 (en) * 2000-03-31 2001-10-11 Curagen Corporation G-protein coupled receptors and nucleic acids encoding same
WO2001087937A2 (en) * 2000-05-18 2001-11-22 Incyte Genomics, Inc. G-protein coupled receptors
GB2365868A (en) * 2000-05-30 2002-02-27 Smithkline Beecham Corp Polynucleotides and polypeptides of the G-protein coupled receptor AXOR87
WO2001098330A2 (en) * 2000-06-20 2001-12-27 Euroscreen S.A. A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS
WO2002002767A1 (en) * 2000-07-04 2002-01-10 Takeda Chemical Industries, Ltd. Novel g protein-coupled receptor protein and dna thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 3 February 2001 (2001-02-03), MUZNY D.M. ET AL.: "Homo sapiens chromosome 12 clone RP11-324E6, WORKING DRAFT SEQUENCE, 30 unordered pieces", XP002237737, Database accession no. AC026333 *
See also references of EP1379656A2 *
ULLOA-AGUIRRE A ET AL: "Structure-activity relationships of G protein-coupled receptors.", ARCHIVES OF MEDICAL RESEARCH. MEXICO, vol. 30, no. 6, November 1999 (1999-11-01), pages 420 - 435, XP002237736, ISSN: 0188-4409 *

Also Published As

Publication number Publication date
US20030171541A1 (en) 2003-09-11
AU2002303091B2 (en) 2006-11-09
MXPA03007270A (en) 2003-12-04
WO2002083736A2 (en) 2002-10-24
EP1379656A2 (en) 2004-01-14
CA2438107A1 (en) 2002-10-24
JP2005503124A (en) 2005-02-03

Similar Documents

Publication Publication Date Title
WO2002002624A3 (en) B7-like molecules and uses thereof
WO2002024891A3 (en) B7-like molecules and uses thereof
WO2002000724A3 (en) Thymic stromal lymphopoietin receptor molecules and uses thereof
WO2002008285A3 (en) Il-17 molecules and uses thereof
WO2001070977A3 (en) Fibroblast growth factor receptor-like molecules and uses thereof
WO2001092308A3 (en) Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
WO2002020762A8 (en) Tnf receptor-like molecules and uses thereof
WO2001068859A3 (en) Il-17 receptor like molecules and uses thereof
WO2001068705A3 (en) Il-17 receptor like molecules and uses thereof
WO2003060071A3 (en) Albumin fusion proteins
WO2001079443A3 (en) Albumin fusion proteins
WO2001068854A3 (en) Fibroblast growth factor-like molecules and uses thereof
WO2003024991A3 (en) Tall-1 receptor molecules and uses thereof
WO2003087338A3 (en) Her-2 receptor tyrosine kinase molecules and uses thereof
WO2002000723A3 (en) Thymic stromal lymphopoietin receptor molecules and uses thereof
WO2001042474A3 (en) Interferon-like molecules and uses thereof
WO2002010388A3 (en) C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF
WO2002097046A3 (en) B7 related protein-2 molecules and uses thereof
WO2005019259A3 (en) Variants of interleukin-1 receptor antagonist: compositions and uses thereof
WO2001074903A3 (en) Cd20/ige-receptor like molecules and uses thereof
PL374550A1 (en) Il-17 like molecules and uses thereof
WO2002014489A3 (en) Leucine-rich repeat-containing g-protein coupled receptor-8 molecules and uses thereof
WO2004058949A3 (en) Wnt-1 inhibitory factor-1 (wif-1) molecules and uses thereof
WO2003068943A3 (en) Secreted proteins
WO2002099108A3 (en) Atp-binding cassette transporter-like molecules and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002303091

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2438107

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002581491

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/007270

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002731091

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002731091

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002731091

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002303091

Country of ref document: AU